Previous close | 9.90 |
Open | 9.90 |
Bid | 1.70 |
Ask | 4.80 |
Strike | 15.00 |
Expiry date | 2024-07-19 |
Day's range | 9.90 - 9.90 |
Contract range | N/A |
Volume | |
Open interest | 58 |
Key Insights Given the large stake in the stock by institutions, Cullinan Therapeutics' stock price might be vulnerable...
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatmentCAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after pr
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024. The fireside chat is scheduled for Wednesday, M